Kornimate/medical-research-clean huggingface dataset:
the predictive biomarkers in patients with locally advanced non-small cell lung cancer

Conditions: Locally Advanced Non-small Cell Lung Cancer

Summary: this study is a prospective cohort study to evaluate the peripheral blood lymphocyte subsets as predicative biomarkers reflecting the efficacy and toxicity in patients with locally advanced non-small cell lung cancer (nsclc) received chemoradiotherapy (crt) with or without immune checkpoint inhibitors (icis).

all patients had a pathologically confirmed locally advanced nsclc according to the 8th ajcc staging system and received definitive radiotherapy, concurrently or sequentially combined with platinum-based doublet chemotherapy. the peripheral blood samples at various time points including before radiation, 4 weeks after beginning of radiation, the end of radiation, 1 month post radiation, and 1 month post consolidation immunotherapy were collected for lymphocyte subsets detection. the subjects will be divided into two groups according to whether patients received icis, namely, nsclc patients received crt plus icis and nsclc patients received crt.

Eligibility criteria:
inclusion criteria: 1. age 18-75 years; ecog score 0-2. 2. pathologically confirmed locally advanced nsclc according to the 8th ajcc staging system. 3. received definitive radiotherapy, concurrently or sequentially combined with platinum-based doublet chemotherapy. 4. no serious medical diseases and dysfunction of major organs, such as blood routine, liver, kidney, heart and lung function. exclusion criteria: 1. pathologic type was adenocarcinoma with egfr gene mutation or alk gene rearrangement. 2. patients with other active malignancies within 5 years or at the same time. 3. active or previously documented autoimmune or inflammatory diseases (including inflammatory bowel disease, diverticulitis \[except diverticular disease\], systemic lupus erythematosus, sarcoidosis syndrome, wegener' s syndrome). 4. history of allogeneic organ transplantation. 5. history of active primary immunodeficiency. 6. patients with uncontrolled concurrent diseases, including but not limited to persistent or active infection (including tuberculosis, hepatitis b, hepatitis c, human immunodeficiency virus, etc.), symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled arrhythmia, active interstitial lung disease, severe chronic gastrointestinal disease with diarrhea or mental illness. 7. women of child-bearing potential who are pregnant or breastfeeding. 8. the investigator judged other situations not suitable for inclusion in this study.

Keywords: peripheral blood lymphocyte subsets
a clinical trial in subjects with atopic dermatitis (part 1)

Conditions: Atopic Dermatitis

Summary: a phase 2, multicenter, adaptive 2-part clinical trial designed to evaluate the safety and efficacy of adx-629 alone and in combination with standard-of-care in adults with atopic dermatitis.

the trial is divided into 2 parts; the first part of the trial (part 1) is open label, and the second part (part 2) is randomized, double-blind, and placebo controlled. in part 1, approximately 10 subjects will receive open-label adx-629 twice daily for 90 days. in part 2, approximately 40 subjects will be randomized to receive either adx-629 or matching placebo twice daily for 90 days. patients who are interested in participating will be provided detailed information about the study including description of study assessments/procedures, possible side-effects, alternative treatments, and potential benefits.

Eligibility criteria:
inclusion criteria: * adults ≥18 years of age * history of atopic dermatitis, according to american academy of dermatology criteria, that has been present for at least 6 months * mild, moderate, or severe atopic dermatitis, defined as an iga score of ≥2 at baseline * not pregnant, breastfeeding, or lactating and agree to use a highly effective method of acceptable contraceptive for the trial duration, if applicable exclusion criteria: * presence of clinically significant kidney disease or an estimated gloverular filtration rate (egfr) of less than or equal to 45 milliliters/min/1.73 m2 during screening * history of any unstable chronic diseases/conditions, clinically significant abnormalities, or findings, that in the opinion of the investigator, could compromise subject safety or affect the conduct of the trial

Keywords: eczema atopic adaptive aldeyra adx-629 reactive aldehyde species (rasp)
effect of virtual reality therapy on dysphagia in wallenberg syndrome

Conditions: Wallenberg Syndrome

Summary: the goal of this clinical trial is to learn about on dysphagia in wallenberg syndrome. the main questions it aims to answer are: the efficacy of virtual reality therapy in the rehabilitation of patients with dysphagia in wallenberg syndrome. participants received conventional dysphagia treatment and virtual reality therapy once a day for 14 days. researchers compared the control group to see the effect and mechanism of virtual reality therapy.

virtual reality technology has revolutionized various fields, and its application in rehabilitation medicine is particularly noteworthy. virtual reality provides immersive environments that simulate real-life situations, making it an invaluable tool in the rehabilitation process. the goal of this clinical trial is to learn about on dysphagia in wallenberg syndrome. the main questions it aims to answer are: the efficacy of virtual reality therapy in the rehabilitation of patients with dysphagia in wallenberg syndrome. participants received conventional dysphagia treatment and virtual reality therapy once a day for 14 days. researchers compared the control group to see the effect and mechanism of virtual reality therapy.

Eligibility criteria:
inclusion criteria: * age ranged from 18-85 years and right-handed; * first onset, vital signs stable and conscious; * the dysphagia confirmed by videofluoroscopic swallowing study; * no cognitive impairment, the mini-mental state examination score: \>17 for those with an illiterate education, \>20 for those with an elementary education, and \>24 for those with a secondary education and above; * cranial integrity without craniotomy and/or craniectomy; * patient and/or his/her relative agrees and signs written informed consent. exclusion criteria: * combined ischemic foci at other sites; * presence of organic swallowing dysfunction or pre-existing dysphagia due to parkinson's disease, dementia, and others; * severe cardiac, pulmonary, hepatic, and renal insufficiency and vital organ failure; * infected or broken skin on the head; * poorly controlled epilepsy; * poor patient compliance.
the effect of glaucoma drops on of the duration of a pure intraocular gas bubble

Conditions: Scleral Buckling

Summary: a controlled clinical study comparing the effect of topical aqueous suppressants on intraocular gas duration.

a prospective, randomized study comparing the effects of topical aqueous suppressants on intraocular gas duration following scleral buckling and pneumatic retinopexy

Eligibility criteria:
inclusion criteria: * ability to provide written informed consent and comply with study assessments for the full duration of the study. * have undergone eye surgery including scleral buckling or pneumatic retinopexy for treatment of retinal detachment other condition at the discretion of the investigator. exclusion criteria: * prior surgery to treat glaucoma. * current use of glaucoma eye drops. * absence of a lens in the eye or presence of a lens implant in front of the iris (colored part of your eye). * allergy or contraindication to any of the glaucoma drops being used in this study (e.g., sulfa allergy, asthma, chronic obstructive pulmonary disease (bronchitis or emphysema), slow heart rate).

Keywords: eye pneumatic retinopexy topical
diabetes scorecard educational intervention study

Conditions: Type 2 Diabetes

Summary: the purpose of this study is to see if the use of a diabetic scorecard during clinic visits can improve glycemic control, blood pressure control, ldl-cholesterol, aspirin usage, and amount of exercise in adults over age 40 with uncontrolled type ii diabetes.


Eligibility criteria:
inclusion criteria: * uncontrolled type ii diabetes (hba1c ≥ 8%) exclusion criteria: * type i diabetes * hba1c \< 8% * inability to understand the diabetes scorecard due to condition (i.e. dementia, mental retardation, etc) or language barrier * pregnancy * planning to move within the next year
gut microbiota in major depressive disorders with and without rapid eye movement behavior disorder

Conditions: Gut Microbiota

Summary: the purpose of this study is to identify the variations in gut microbiota compositions between two subtypes of major depressive disorder.

objective: to identify the variations in gut microbiota compositions between two subtypes of major depressive disorder (mdd), namely those with and without rem sleep behavior disorder (rbd). to correlate the microbiota composition with depressive severity and prodromal markers of α-synucleinopathy. design: case-control study setting: established clinical cohorts consisting of patients with comorbid mdd+rbd and mdd only and a group of sexand age-matched healthy control participants: patients with comorbid mdd+rbd (n=55), patients with mdd only (n=55), and healthy control (n=55). main outcome measures: the abundance and composition of gut microbiota, severity of depressive symptoms, and prodromal markers of α-synucleinopathy.

Eligibility criteria:
inclusion criteria: 1. age-and sex-matched with mdd+rbd subjects; 2. free of psychiatric disorders based on m.i.n.i.; 3. without a personal history or a family history of rbd or neurodegenerative diseases (i.e. dementia and pd) 4. free of rbd symptoms or rwsa by vpsg exclusion criteria: 1. presence of narcolepsy and other neurodegenerative diseases that may give rise to rbd and rwsa; 2. severe psychiatric illness that could not permit a valid written informed consent or otherwise is not suitable for participating in a study; 3. use of antibiotics within one month and the use of probiotics within three days prior to sample collection; 4. pre-existing or post-operation of gastrointestinal diseases (e.g. inflammatory bowel disease, gastrointestinal cancer).

Keywords: major depressive neurodegeneration
everlinq endoavf post market study

Conditions: Chronic Kidney Disease

Summary: prospective, multi-center study to evaluate the everlinq endoavf system when used to create an endovascular arteriovenous fistula (endoavf) for patients who require vascular access for hemodialysis.


Eligibility criteria:
inclusion criteria: * adult (age \>18 years old) * currently on chronic dialysis or expected to be started on chronic dialysis within 3 months of planned endoavf creation * target treatment vein diameter(s) for fistula creation ≥ 2.0 mm as measured via duplex ultrasound or venogram * target treatment artery diameter(s) for fistula creation ≥ 2.0 mm as measured via duplex ultrasound or arteriogram * both radial and ulnar artery flow to the hand, as confirmed with duplex ultrasound and/or allen's test (i.e.: palmar arch) exclusion criteria: * known central venous stenosis or central vein narrowing \> 50% based on imaging on the same side as the planned avf creation * absence of perforator feeding the target cannulation vein(s) via venogram * occlusion or stenosis \>50% of target cannulation cephalic or basilic vein * significantly compromised (≥50% stenosis) flow in the treatment arm * documented ejection fraction (ef) ≤35% in the last 6 months * pregnant women * new york heart association (nyha) class iii or iv heart failure * hypercoagulable state * known bleeding diathesis * documented history of drug abuse including intravenous drugs within six months of avf creation * "planned" concomitant major surgical procedure within 6 months of enrollment or previous major surgery within 30 days of enrollment * known allergy to contrast dye which cannot be adequately pre-medicated * known adverse effects to sedation and/or anesthesia which cannot be adequately pre-medicated * evidence of active infections on the day of the index procedure * estimated life expectancy \< 1 year * patient is not willing to provide written informed consent, is not geographically stable and/or not willing to comply with required follow-up * patient with a target cannulation vein that is \> 6mm deep that would require a transposition procedure, defined as the elevation of a target cannulation vein and the creation of a new av fistula * patient is not willing to undergo a 2nd stage procedure as defined in section 4.5.3 of the study protocol.
safety of 25 and 50 mg proellex® in the treatment of women with symptomatic uterine fibroids

Conditions: Uterine Fibroids

Summary: safety and efficacy study of 25 and 50 mg doses of proellex

the study is intended to provide more abundant safety and efficacy data of both the 25 and 50 mg doses of proellex than zpu-301, zpu-302, zpu-303 and zpu-304 alone.

Eligibility criteria:
inclusion criteria: * at least 1 uterine fibroid must be identifiable and measurable by transvaginal ultrasound (tvu) * subject has a menstrual cycle lasting from 20 to 40 days. * subject must have satisfactorily completed all study visits from the previous study in which she participated: zpu-301, zpu-302, zpu-303, or zpu-304 exclusion criteria: * subjects who have not participated in 1 of the previous repros studies: zpu-301, zpu-302, zpu-303, or zpu-304. * subjects who met treatment stopping rules as per the dili guidance requirements while participating in zpu-301, zpu-302, zpu-303, or zpu-304

Keywords: uterine fibroids
patient convenience study

Conditions: Atrial Fibrillation

Summary: the aim of this non-interventional study is to describe patient's perception of anticoagulant treatment when using pradaxa® to prevent stroke and systemic embolism while suffering from atrial fibrillation (according to its approved indication in the approved dosages of 110 mg or 150 mg twice daily) in comparison to standard care using vitamin k antagonist (vka).


Eligibility criteria:
inclusion criteria: cohort a: 1. a. written informed consent prior to participation 2. a. female and male patients \>= 18 years of age with a diagnosis of non-valvular atrial fibrillation. 3. a. at least 3 months of continuous vka treatment for stroke prevention prior to baseline assessment. 4. a. patients switched to pradaxa® according summary of product characteristics and physician's discretion. or cohort b: 1. b. written informed consent prior to participation. 2. b. female and male patients \>= 18 years of age newly diagnosed with non-valvular atrial fibrillation and no previous treatment for stroke prevention (no use of any oral anticoagulant (oac) within one year prior to enrolment). 3. b. stroke prevention treatment initiated with pradaxa® or vka according to summary of product characteristics and physician's discretion. exclusion criteria: 1. contraindication to the use of pradaxa® or vka as described in the summary of product characteristics (smpc). 2. patients receiving pradaxa® or vka for any other condition than stroke prevention in atrial fibrillation. 3. current participation in any clinical trial of a drug or device. 4. current participation in an european registry on the use of oral anticoagulation in af.
thoracentesis qi study

Conditions: Pleural Effusion

Summary: researchers will compare 3 standard of care methods of pleural fluid drainage during therapeutic thoracentesis. patients are randomized to manual aspiration, vacuum bottle drainage or wall suction methods. primary outcome is procedural time with secondary outcomes of pain and dyspnea scores.


Eligibility criteria:
inclusion criteria: * age \>18 * evidence of pleural effusion on imaging * clinical indication for thoracentesis exclusion criteria: * age \<18 * standard contraindication for thoracentesis procedure * patients on positive pressure ventilation * patients who have opted out of research in epic

Keywords: pleural effusion thoracentesis wall suction manual aspiration vacuum bottle drainage
ida (immunothérapie de la dermatite atopique) adult - immunotherapy in atopic dermatitis

Conditions: Atopic Dermatitis

Summary: atopic dermatitis (ad) is a chronic inflammatory disease of the skin. ad is very frequent, and involves t lymphocytes cells. measles vaccination, as well as measles vaccine, induces a temporary immunosuppression; furthermore, an improvement of ad has been observed during measles infection. this trial is aimed at demonstrating that measles vaccine is able to create an immunomodulation and to improve ad symptoms. 30 adult patients of both sexes with moderate to severe ad will be randomly assigned to measles vaccine (rouvax ®), or placebo (vehicle) and follow-up for 45 days. the primary outcome is the effect of anti-measles vaccination on the t cell responses in patients; other outcomes include: clinical evolution of ad, as measured by the scorad, the evolution of blood level of measles specific ige and antibodies; evolution of other biomarkers and phenotypic characteristics of t lymphocytes.

atopic dermatitis (ad) is a chronic inflammatory disease of the skin. ad is very frequent, and involves t lymphocytes cells. measles vaccination, as well as measles vaccine, induces a temporary immunosuppression; furthermore, an improvement of ad has been observed during measles infection. this trial is aimed at demonstrating that measles vaccine is able to create an immunomodulation and to improve ad symptoms.

Eligibility criteria:
inclusion criteria: * adults patients of both sexes, with moderate to severe atopic dermatitis (scorad (score for atopic dermatitis) ≥ 15). exclusion criteria: * hypersensititvity or contra-indication to a rouvax® component, tubertest® component, to egg proteins, immunological deficiency, pregnancy, neomycin * allergy, * systemic immnosuppressive treatment in the previous 3 months, * topic immunosuppressive treatment during the week preceeding the inclusion (gluco-corticoid, or immunosuppressive agent), * fever or acute disease (the inclusion must be postpone in such cases).

Keywords: atopic dermatitis immunosuppression measles vaccine t lymphocytes atopic dermatitis in adults
reducing sympathetic activity through ultrasound-based renal denervation in excessive cardiovascular risk populations.

Conditions: Chronic Kidney Diseases; Heart Failure; End Stage Renal Disease

Summary: the is a non-randomized pilot trial, open-label evaluation of the physiologic response of native kidney denervation using the paradise denervation system in ckd, end stage renal disease (esrd), and heart failure (hf)

there is unequivocal evidence for an important contribution of increased renal sympathetic nerve activity to cardiovascular (cv) morbidity and mortality in high risk patient cohorts with ckd, esrd and hf. the availability of a highly effective catheter-based ultrasound device to selectively target renal nerves provides a potential unique opportunity to improve cv outcomes in these patients, a proposition that now needs to be tested in initial pilot trials and subsequent appropriately designed randomized controlled trials.

Eligibility criteria:
inclusion criteria: * both male and female patients * ages between 18-75 years of age * individual is competent and willing to provide written, informed consent to participate in this clinical study with either * ckd stage 3a/b or * esrd on stable renal replacement therapy or * mild to moderate heart failure with reduced ejection fraction exclusion criteria: * ineligible anatomy * prior treatment with other devices for hypertension including but not limited to rox coupler (rox medical) , mobius stent, and/or the cvrx (cvrx inc) barostimulator device. * individual has experienced a myocardial infarction, unstable angina, or a cerebrovascular accident within 3 months of the screening visit. * documented history of chronic active inflammatory bowel disorders such as crohn's disease or ulcerative colitis. * individual has clinically significant cardiac structural valvular disease, unless corrected by a properly functional prosthetic valve * individual has been admitted for inpatient hospitalization for decompensated hf in the previous month * female participants of childbearing potential must have a negative pregnancy test prior to treatment. * individual has a known, unresolved history of drug use or alcohol dependency, lacks the ability to comprehend or follow instructions, or would be unlikely or unable to comply with study follow-up requirements. * individual is currently enrolled in another investigational drug or device trial. note: for the purpose of this protocol, participants involved in extended follow-up trials for products that were investigational but are currently commercially available are not considered enrolled in an investigational trial. * individual has a disease or condition (aside from ckd, esrd, and hfref) that may limit their life expectancy to \< 1 year.

Keywords: renal denervation sympathetic nervous system
central sensitization in familial mediterranean fever (fmf)

Conditions: Familial Mediterranean Fever; Central Sensitisation

Summary: familial mediterranean fever (fmf) is an autosomal recessive inherited disease with a course of autoinflammation, which is characterized by the episodes of fever and serositis. central sensitization (cs) is defined as increased response to normal or sub-threshold stimuli of central nervous system and its close relationship with many rheumatological diseases has been demonstrated in several studies. however, there are no data on the frequency of cs in fmf patients.

familial mediterranean fever (fmf) is a self-limiting autoinflammatory disease with well-defined genetic and clinical features. recurrent episodes of fever and serositis accompanied by increased acute phase reactants and good response to colchicine are the core components of the disease. the frequency of this disease, which is common in eastern mediterranean countries, is variable according to regions, but it is reported as 1/1000. in the pathogenesis of the disease, the mutation of the mefv (mediterranean fever) gene, which is located on the 16th chromosome and encodes the pyrin protein, is known as the basic mechanism.in rheumatic diseases, inflammatory mediators cause cs by first creating changes in the regulation of pain in peripheral neurons and then in spinal and supraspinal pathways. stimulation of peripheral nerves by mediators released during inflammation results in neurogenic inflammation, which is among the peripheral sensitization (ps) mechanisms. ps is defined as the increased sensitivity of nociceptive neurons to normal or below-threshold stimuli and constitutes the first step in the development of cs.similar to other autoimmune diseases, it is possible that the neuroinflammatory process triggers peripheral and central sensitization mechanisms in fmf patients and affects pain pathways.

Eligibility criteria:
inclusion criteria: * agree to participate in the study exclusion criteria: * had another systemic inflammatory rheumatic diseases * using centrally acting pain medications (e.g., pregabalin, duloxetine, opioids) or glucocorticoids (\>10 mg prednisone or its equivalent)

Keywords: familial mediterranean fever central sensitization central sensitization inventory